| Document |
Document Title |
|
WO/2016/009322A1 |
The present invention relates to the amorphous form of macitentan and to new crystalline forms thereof. The invention also relates to processes for the preparation of the new compounds, to the pharmaceutical compositions comprising them ...
|
|
WO/2016/000476A1 |
The present invention relates to the technical field of ibrutinib, particularly to the technical field of ibrutinib intermediate compounds and preparation methods thereof. The intermediate compounds are represented by formula (A), wherei...
|
|
WO/2016/001851A1 |
The present application relate to processes for preparing Ticagrelor and to intermediates that are useful in the processes.
|
|
WO/2016/001118A1 |
The invention relates to the compounds of general formula (I) and the agrochemically acceptable salts thereof and to the use thereof in the field of plant protection.
|
|
WO/2016/004180A1 |
The present invention provides inhibitors of O-GlcNAc transferase. Typically, the inhibitors are quinolinone-6-sulfonamides. The invention also provides pharmaceutical compositions thereof and methods for using the same in diabetes and c...
|
|
WO/2016/001204A1 |
Primarily, the present invention relates to compounds of the formula (I) defined below and to the use thereof as herbicides, in particular for controlling broad-leaved weeds and/or weed grasses in crops of useful plants and/or as plant g...
|
|
WO/2016/001419A1 |
Pharmaceutical compositions for topical administration for the treatment of psoriasis are described, containing as active ingredient therapeutically effective quantities of 4,6-dimethyl-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine (I) and...
|
|
WO/2016/004136A1 |
Disclosed are chemical entities which are compounds of formula (I); or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra', Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations d...
|
|
WO/2015/197028A1 |
Provided herein are compounds of Formula (I), or a stereoisomer, a geometric isomer, an enantiomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which are used in th...
|
|
WO/2015/199572A1 |
The invention relates to a novel fungicidal agent in the form of a salt associate having the structural formula shown. The agent can be used for treating diseases caused by fungi, and also for preventing fungal damage to various mater...
|
|
WO/2015/197981A1 |
The invention relates to the probes of formula (I); in which: X1 = NH, O or S; X2 = O or S; SE is a labile group, which may be removed under the action of a stimulus which may in particular be the presence of an enzyme, of a chemical com...
|
|
WO/2015/193165A1 |
The present invention relates to a process for the preparation of triazolo[4,5-d] pyrimidine cyclopentane compounds of formula (I), and pharmaceutically acceptable salts thereof. The invention also provides novel compounds that can be us...
|
|
WO/2015/195423A1 |
The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in p...
|
|
WO/2015/194764A2 |
The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A ...
|
|
WO/2015/195478A1 |
Novel processes, and intermediates, for making alkylated arylpiperazine and alkylated arylpiperidine compounds of the general formulas (I) and (VII), respectively wherein, R1 and R2 are individually selected from hydrogen, alkyl, substit...
|
|
WO/2015/191745A1 |
The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A', W1, W2, W3, R1, R2, and R3 are described herein. The compounds are inhibitors to the...
|
|
WO/2015/189595A1 |
The invention provides compounds of the formula: wherein L1 and L2 are independently selected from O and S; R1 is C3-C6straight or branched alkyl, C3-C7cycloalkyl, C5-C7cycloalkenyl, adamantly, phenyl or saturated heterocyclyl, any of wh...
|
|
WO/2015/191179A1 |
The present invention provides for the novel method for the inhibition of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion having Formulas I-XI in lowering serum lipids and in the prevention and tr...
|
|
WO/2015/191846A1 |
The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4- morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
|
|
WO/2015/188318A1 |
A concise, efficient and cost-and time-saving process for the preparation of a quinazoline derivative of formula (A) given below: which is an intermediate for making gefitinib or gefitinib itself, comprising reacting a compound of formul...
|
|
WO/2015/187088A1 |
A compound of formula I, (I) or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer.
|
|
WO/2015/182547A1 |
To provide an organic thin-film light-emitting element in which light-emitting efficiency, drive voltage, and service life are all improved by a fluoranthene derivative represented by a specific structure. (In the formula: Ar represents ...
|
|
WO/2015/182769A1 |
Provided are compounds shown by general formula (1) as an organic electroluminescent device having high efficiency, low voltage driving, and long life and a material making this possible, especially an electron transport material, method...
|
|
WO/2015/182682A1 |
The present invention pertains to a Sonogashira carbonylation reaction using two types of gas, as well as novel crystals capable of controlling the heat of reaction of this Sonogashira carbonylation reaction, and a method for the product...
|
|
WO/2015/183838A1 |
The present disclosure provides N-hydroxylamino-barbituric acid compounds of formulae (1)- (4), pharmaceutical compositions and kits comprising them, and methods of using such compounds or pharmaceutical compositions. The present disclos...
|
|
WO/2015/181186A1 |
The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions con...
|
|
WO/2015/128873A9 |
The present invention relates to 6-aryl-4-phenylamino quinazolines of formula I wherein, R and R´ are as herein described. The present invention particularly relates to synthesis and anticancer and phoshpoinositide-3-kinase-α (PI3K-α ...
|
|
WO/2015/178608A2 |
The present invention provides: a 3,4-dihydroquinazoline derivative or a pharmaceutically acceptable salt thereof, which blocks the intracellular influx of calcium ion, an secondary signal transducer essential for the proliferation and g...
|
|
WO/2015/178589A1 |
Related are: an organic compound represented by Chemical Formula 1; a composition for an organic electroluminescent device, which includes the organic compound; an organic electroluminescent device that employs the organic compound or th...
|
|
WO/2015/175750A1 |
Compounds that target vascular endothelial growth factor receptors for therapy and imaging are disclosed. Methods for making the compounds and detecting or imaging cells expressing VEGFR using the compounds are also provided. In accordan...
|
|
WO/2015/172203A1 |
The present invention relates to methods for inhibiting necroptosis; screening methods for identifying compounds which inhibit necroptosis; and compounds for the inhibition of necroptosis, which may be useful in the treatment of conditio...
|
|
WO/2015/149130A9 |
The present invention provides ligands which bind to MR1, some of which induce MR1 to bind to MAIT cells thereby activating or inhibiting MAIT cell activation.
|
|
WO/2015/172889A1 |
The invention relates to new peptide nucleic acid monomers and peptide nucleic acid oligomers comprising a dialkylamine side chain substituted with phosphonic acid ester group(s) or phosphonic acid group(s), and to the uses thereof.
|
|
WO/2015/175331A1 |
Methods of treating kidney disease and protecting podocytes from injury are provided. Methods of screening agents for the treatment of kidney disease are also provided. In addition, methods of identifying structural or functional defects...
|
|
WO/2015/173329A1 |
The invention relates to antibacterial compounds of formula I, wherein R1 is H or halogen; R2 is the group M; R3 is H or halogen; M is MA or MB wherein A is a bond or C≡C; R1A is H or halogen; R2A is H, alkoxy or halogen; R3A is H, alk...
|
|
WO/2015/174421A1 |
The present invention provides: a pyrimidine derivative that can be applied to an agricultural chemical or medicine having excellent pharmacological activity and has a fluorine-containing substituent group; and a method for producing sai...
|
|
WO/2015/175707A1 |
The present invention provides compounds I and II and compositions thereof for use in the modulation of Hsp70. In some embodiments, the present invention provides a method for inhibiting Hsp70 activity. In some embodiments, the present i...
|
|
WO/2015/169677A1 |
The application relates to novel sulfoximine substituted quinazoline derivatives of formula (I) wherein Ar, R1, R2 and R3 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) k...
|
|
WO/2015/170345A1 |
The present invention discloses pharmaceutical co-crystals of gefitinib with co-crystal former selected from aliphatic dicarboxylic acid and aromatic di and tricarboxylic acids which exhibit better solubility, dissolution rate hence enha...
|
|
WO/2015/170600A1 |
[Problem] To provide a 5-(trifluoromethyl)pyrimidine derivative that is useful as an intermediate for pharmaceuticals and agrochemicals and as an intermediate for electronic materials, and a production method therefor. [Solution] 2,4-dic...
|
|
WO/2015/169718A1 |
The invention relates to novel compounds of formula (I), in which R1, R2, n, V1, V2, Q, W, X, and Y have the meanings specified in the description, to a plurality of methods, and to intermediate products for producing said compounds, and...
|
|
WO/2015/169999A1 |
Compounds of formula (I), wherein R1-8 are as defined in the claims, exhibit a positive allosteric GABAB modulator effect and are thus useful as positive allosteric modulators of the GABAB receptor.
|
|
WO/2015/169932A1 |
The present invention relates to erlotinib hydrochloride Form A that includes no detectable erlotinib hydrochloride Form B; as determined by X-ray powder diffraction analysis that includes a differentiation resolution and a 2-theta scan ...
|
|
WO/2015/170878A1 |
The present invention relates to: a conjugate for photodynamic diagnosis or therapy, in which folic acid is coupled to a photosensitizer or a near-infrared fluorescent dye through an intracellular cleavable link; and a composition for ph...
|
|
WO/2015/165279A1 |
Provided are new polyfluoro-substituted pyrazolopyrimidine compounds or salts represented by formulae (I) to (IX), a preparation method therefor, and a method for using said compounds and a preparation thereof to treat and inhibit autoim...
|
|
WO/2015/168466A1 |
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. ...
|
|
WO/2015/168079A1 |
Compounds (I) and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, ...
|
|
WO/2015/162538A1 |
The invention relates to heterocyclic compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their pharmaceutical compositions for use in medicine for the treatment of ...
|
|
WO/2015/164294A1 |
Methods and compounds are described for treating solid tumors, and in particular, malignant, neoplastic solid tumors such as glioblastoma and medulloblastoma, by inhibiting protein kinase MRK/ZAK activity. Also provided are pharmaceutica...
|
|
WO/2015/161479A1 |
Provided is use of a pyrimidine compound or a pharmaceutically acceptable salt thereof in preparation of an anti-cervical cancer medicament. Research of the present invention has found that the above-mentioned pyrimidine compound can be ...
|
